Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL

Summary

This is a phase I clinical study to evaluate the safety and tolerability of pCAR-19B in adults with relapsed or refractory B-ALL, and to obtain the maximum tolerated dose of pCAR-19B and phase II Recommended dose.

Timeline

Start

2020-10-26

Primary completion

2022-01-30

Completion

2022-03-28

Publications

• Li H, Ge T, Huang M, Zhang W, Li Z, Xiao M, Gao L. Application of metagenomic next-generation sequencing in bloodstream infection regarding immunosuppression. J Infect. 2023 May;86(5):508-512. doi: 10.1016/j.jinf.2023.02.008. Epub 2023 Feb 10. No abstract available.

Drugs

Indications